BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 18, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2023

View Archived Issues
Red blood cells coagulating

Blood thinner class dissolves blood clots without increasing bleeding risk

Blood clots can lead to life-threatening conditions such as deep vein thrombosis, heart attack, pulmonary embolism and stroke. Blood thinners are essential in the treatment and prevention of blood clots but carry a significant risk of bleeding as they target enzymes essential for blood clotting. Researchers at the University of British Columbia (UBC) and the University of Michigan have developed a new class of blood thinners that can specifically target clots without increasing the risk of bleeding. Read More

Transcriptomic atlas classifies 40 brain diseases

The map of the genetic activity of the risk genes that affect the central nervous system (CNS) reveals the molecular signatures associated with the neurological pathologies in this organ. A study by researchers at McGill University in Canada and the Allen Institute for Brain Science in Washington compared 40 brain diseases with this technology and classified them into five groups whose members shared the same transcriptional pattern. Read More
Liver

Viscient identifies drug candidate for NASH by using 3D bioprinted models

Viscient Bio Inc. has identified a drug candidate to treat nonalcoholic steatohepatitis (NASH)... Read More
Candida auris

Third-generation broad-spectrum antifungal SF-001 disclosed

Amphotericin B is an antifungal agent with activity against a wide range of opportunistic fungal... Read More

Vrise Therapeutics patents new GTPase KRAS G12C inhibitors for cancer

Vrise Therapeutics Inc. has disclosed GTPase KRAS G12C inhibitors reported to be useful for the... Read More
Microscopic image of the blood-brain barrier in a mouse.

Lantern Pharma’s AI algorithms shown to predict blood-brain barrier permeability of compounds

Lantern Pharma Inc. has developed highly accurate artificial intelligence (AI) algorithms to predict... Read More

BB-3008, novel HPK1 inhibitor with promising safety and efficacy in multiple solid tumor models

Researchers from Broadenbio Co. Ltd. presented the discovery and preclinical evaluation of BB-... Read More

Wigen Biomedicine divulges new PARP inhibitors for cancer

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized tricyclic compounds acting... Read More
Macrophage and cancer cell

Incyte provides details on preclinical profile of new PI3Kγ inhibitor INCB-098377

Macrophages are specialized immune cells that can either stimulate or inhibit inflammation. Studies in mice suggest that phosphoinositide 3-kinase γ (PI3Kγ), a key mediator in macrophage signaling pathways predominantly expressed in myeloid cells, may promote immune suppression both in inflammation and in the tumor microenvironment. Read More

University of Vermont describes new PAC1 receptor antagonists

The University of Vermont has identified ADCYAP receptor type I (PAC1 receptor) antagonists reported to be useful for the treatment of pain, eating, neurological and stress disorders, substance abuse and dependency. Read More

RAB13 as key gene in metastasis-associated cell cluster and potential therapeutic target for ovarian cancer

Previous studies have shown that ovarian cancer (OC) has strong tumor heterogeneity, resulting in high recurrence and metastasis rates. In recently published work, researchers from Capital Medical University (CMU) applied single-cell transcriptomics to identify metastasis-associated cell clusters and key genes involved in OC metastasis. Read More
Sickle cell illustration

Ex vivo prime editing could reverse sickle cell disease

A proof of concept of ex vivo genetic modification of cells from patients and their transplantation in mice has demonstrated, for the first time, the therapeutic possibilities of prime editing in sickle cell disease (SCD). Read More

Chinese researchers present new azaphenothiazine derivatives for endometrial cancer

Researchers at China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have divulged azaphenothiazine derivatives reported to be useful for the treatment of endometrial cancer. Read More

New mouse model of HSAN IV carrying the TrkA R649W mutation mimics human disease

Nerve growth factor (NGF) actions are involved in pain perception and mediated via the tyrosine kinase TrkA (tropomyosin receptor kinase A) in neural cells. Mutations in the gene encoding for TrkA cause hereditary sensory and autonomic neuropathy type IV (HSAN IV), a rare autosomal recessive disorder characterized by loss of responses to noxious stimuli, anhidrosis and cognitive impairment. Until now, appropriate animal models to study the mechanisms underlying HSAN IV were missing. Read More
cancer-cell-light.png

Researchers report development of HZ-R078, a novel long-acting STAT3 degrader

The Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway comprises four JAK kinases and seven STAT transcription factors. Among the latter, STAT3 is the best-known oncogene and its essential role in normal tissue makes its complete blockage useless for treatment due to severe side effects. Read More

Idorsia Pharmaceuticals discovers new CCR6 antagonists

Idorsia Pharmaceuticals Ltd. has described C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing